Compile Data Set for Download or QSAR
Report error Found 719 Enz. Inhib. hit(s) with all data for entry = 2951
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351981(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351982(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351984(1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351985(1-(2-((1R,3S,5R)-3-(6- bromopyridin-2- ylcarbamoyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351986(1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351987(1-(2-((1R,3S,5R)-3-(2'- chloro-2- fluorobiphenyl-3...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351988(1-(2-((1R,3S,5R)-3-(2'- chloro-2- fluorobiphenyl-3...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351989(1-(2-((1R,3S,5R)-3-(2- fluoro-3- (trifluoromethoxy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351990(1-(2-((2S,4R)-4-fluoro- 2-(2-fluoro-3- (trifluorom...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351991(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351992(1-(2-((1R,3S,5R)-3-(6- bromopyridin-2- ylcarbamoyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351993(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351994(1-(2-((lR,3S,5R)-3-(2'- chloro-2- fluorobiphenyl-3...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351995((2S,4R)-1-(2-(3-acetyl- 5-(pyrimidin-5-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351996((1R,3S,5R)-2-(2-(3- acetyl-5-(pyrimidin-5- yl)-1H-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351997((2S,4R)-1-(2-(3-acetyl- 5-(4-acetylpiperazin-1- yl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351998((1R,3S,5R)-2-(2-(3- acetyl-5-(pyrimidin-5- yl)-1H-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351999(1-(2-((2S,4R)-2-(3- chloro-2- fluorobenzylcarbamoy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352000(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352001((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352002((2S,4R)-1-(2-(3-acetyl- 5-(2- methoxypyrimidin-5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352003(1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352004((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352005(1-(2-((2S,4R)-2-(6- chloropyridin-2- ylcarbamoyl)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352006(1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386090((2S,4R)-1-(2-(3- acetyl-5-(2- (pyrrolidin-1- yl)py...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352010((2S,4R)-1-(2-(3-acetyl- 5-(2- methoxypyrimidin-5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386092((2S,4R)-1-(2-(3- acetyl-5-(1-acetyl- 1,2,3,6- tetr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386093(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352378(1-(2-((2S,4R)-2-(6- chloropyridin-2- ylcarbamoyl)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352379((2S,4R)-1-(2-(3-acetyl- 5-(4-(pyrimidin-2- yl)pipe...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM352488((2S,4R)-1-(2-(3-acetyl- 5-(4-(5- fluoropyrimidin-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM353069((2S,4R)-1-(2-(3-acetyl- 5-(4-(methylsulfonyl) pipe...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM353441((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354135((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354136(1-(2-((2S,4R)-2-(3- chlorobenzylcarbamoyl)- 4-fluo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354137((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354158(1-(2-((2S,4R)-2-(3- chloro-5- fluorobenzylcarbamoy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354162((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354164((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354171((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354172(1-(2-((2S,4R)-2-(2,2- dimethyl-2,3- dihydrobenzofu...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354176((1R,3S,5R)-2-(2-(3- acetyl-5-(2- methoxypyrimidin...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354177((1R,3S,5R)-2-(2-(3- acetyl-5-(2- methoxypyrimidin-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354178((2S,4R)-1-(2-(3-acetyl- 5-(2-cyanopyrimidin-5- yl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354180((2S,4R)-1-(2-(3-acetyl- 5-(2-fluoropyrimidin-5- yl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354181((2S,4R)-1-(2-(3-acetyl- 5-(2-methylpyrimidin- 5-yl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354185((2S,4R)-1-(2-(3-acetyl- 5-(pyridazin-4-yl)-1H- ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM354187(1-(2-((2S,4R)-2-(6- chloropyrazin-2- ylcarbamoyl)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386161((2S,4R)-1-(2-(3- acetyl-5-(pyridazin- 4-yl)-1H-ind...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 719 total ) | Next | Last >>
Jump to: